Fulcrum Therapeutics (FULC) Retained Earnings: 2019-2025
Historic Retained Earnings for Fulcrum Therapeutics (FULC) over the last 7 years, with Sep 2025 value amounting to -$573.9 million.
- Fulcrum Therapeutics' Retained Earnings fell 14.14% to -$573.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$573.9 million, marking a year-over-year decrease of 14.14%. This contributed to the annual value of -$519.4 million for FY2024, which is 1.91% down from last year.
- According to the latest figures from Q3 2025, Fulcrum Therapeutics' Retained Earnings is -$573.9 million, which was down 3.53% from -$554.3 million recorded in Q2 2025.
- In the past 5 years, Fulcrum Therapeutics' Retained Earnings ranged from a high of -$238.6 million in Q1 2021 and a low of -$573.9 million during Q3 2025.
- For the 3-year period, Fulcrum Therapeutics' Retained Earnings averaged around -$508.9 million, with its median value being -$509.7 million (2023).
- Data for Fulcrum Therapeutics' Retained Earnings shows a maximum YoY slumped of 40.98% (in 2021) over the last 5 years.
- Fulcrum Therapeutics' Retained Earnings (Quarterly) stood at -$302.5 million in 2021, then tumbled by 36.31% to -$412.3 million in 2022, then declined by 23.61% to -$509.7 million in 2023, then decreased by 1.91% to -$519.4 million in 2024, then decreased by 14.14% to -$573.9 million in 2025.
- Its Retained Earnings stands at -$573.9 million for Q3 2025, versus -$554.3 million for Q2 2025 and -$537.1 million for Q1 2025.